LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT WAR 3 : 2002 5 THE PATENT DOCUMENT ATTY. DUCKET NO. 38602–1220 09/897,755 APPLICANT: Peng Cho Tang et al. FILING DATE: 7/3/01 1627

EXAMPLER INITIAL			_	DOG.	MENT	NUMB	8		DATE	NAME	QASS	CA2S	RUNC
	M	2	9	6	8	5	5	7	01/17/61	Burgardt et al.			
	AB	5	4	0	9	9	4	9	04/95	Buzzeti et al.			
	AC	5	3	9	7	7	8	7	63/14/95	Buzzetti et al.			
	AD	5	3	7	4	6	5	2.	12/20/94	Buzzeti et al.			
	Æ	5	1	2	4	3	4	7	06/23/92	Connor et al.		•	
	. AF	5	3	3	0	9	9	2	07/19/94	Fisserstat et al.			
	Æ	. 5	4	6	3	0	5	2	10/31/95	Haga et al.	·	-	7
	ΛH	2	.8	7	2	3	7	2	02/03/59	Hull			
	A	5	2	0	6	2	6	1	04/93	Kawaguchi et al.			
	N	4	8	6	8	3	0	4	09/19/89	Larock et al.			
	AK	5	3	8	2	5	9	3	01/95	Le Baut			
	ÄL	5	2	1	7	9	9	9	06/08/93	Levitzki	·		
	м	4	6	4	2	3	0	9	02/10/87	Michel et al.			
	W	4	8	2	6	8	4	7	05/02/89	Michel et al.			
	AO	5	0	5	1	4	1	7	09/24/91	Nadler et al.			
	AP.	4	9	7	1	9.	9	6	11/20/90	Shiraishi et al.			
	AQ	4	8	5	3	.4	0	3	08/01/89	Shiraishi et al.			
	AR	5	2	٥	2	3	4	1	04/13/93	Shiraishi et al.			
	AS	5	0	5	7	5	3	8	10/15/91	Shiraishi et al.			
	AT	5	0	8	9	5	1	6	02/18/92	Shiraishi et al.			
	ΑU	5	3	2	2	9	5	0	06/94	Sircar et al.			
	۸۷	5	3	٥	. 2	6	0	6	04/12/94	Spada et al.			-
·	۸W	4	9	6	6	8	4	9	10/30/90	Vallee et al.			
						I							

	,	,						FO	BECN PATEN	T DOCUMENTS				
DEAMINER			c	OCU.	UNT N	LIMBEI			DATE	COUNTRY	QASS.	SUS	TRANS	LATION
PATRAL										CONIET	LIAS .	QV22	YES	Ю
	AX	٥	5	6	6	2	6	6	15.1.93	EPO (Barker et al.)		5	- 2.5	,
	AY	9	4	1	4	8	0	8	07.07.94	WO/PCT (Buzzetti et al.)		. :		
	ΑZ	٥	5	2	5	4	7	· 2	03.02.93	EPO (Buzzetti et al.)		7 6		
	BA	9	5	0	1	3	4.	9	12.01.95	WOPCT (Buzzetti et al.)		7		
	88	9	6	1	6	9	6	4	06.06.96	WOPCT (Buzzetti et al.)		7 3		
	BC	0	6	6	2	4	7	3	12,07.95	EPO (Buzzeti et al.)			٠.	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is citation if not in conformance and not considered. Include a copy of the conformance and not considered.	s in conformance with MPEP 609; Draw line this form with next communication to applica

FORM I		•				·	e j	-		ATTY. DE T NO).	SERIA		
is Oli	INI F	FORM	IATIO	ON E	SCL	.OSU	RE ST	FOR . TATE: isary)	APPLICANT'S MENT	38602-1220 APPLICANT: Peng Cho	Tang et	al.,	<u> 1897</u>	<u>,755</u>
18	1 2002	<u>ij</u>								FILING DATE: 7/3/01		GROU	P: 162	
(4) 5 TB	WENGE	_						U.	S. PATENT DOCL	MENTS				
EXAMINER INITIAL			,	DOCU	MENT	NUMB	BR .		DATE	NAME	ax	8 8		FILING DATE
			$oldsymbol{ol}}}}}}}}}}}}}}}}}}$	<u> </u>		L	<u> </u>	L						
			L_	L	_	<u> </u>	<u> </u>	L.				1		
<u> </u>				L_			L.							

		¥						FO	REICN PATEN	IT DOCUMENTS		•		
EXAMINER INITIAL				DOCU	MENT	NUMB	ER		DATE	COUNTRY	GASS	SUB	TRANS	LATION
		-		_	_		,		ļ			CLASS	YES	NO
	<u> </u>	0	6	2	6	3	7	7	11/30/94	EPO (Hagga et al.)				
· · ·	A8	9	7	3	6	8	6	7	1009/97	WOPCT (Howard)				_
. ,	AC	9	2	8	6	7	7	7	11/04/97	Japan				-
/	40	9	5	1	4	6	6	7	06/01/95	WOPCT (Masamune)				
	Æ	3	3	1	0	8	9	1	09/27/84	Germany (Michel et al.)				
	AF	3	4	2	6	4	1	9	01/23/86	Cermany (Michel et al.)				
	AG	9	7	2	5	9	8	6	07/24/97	WOPCT (Sato et al.)				
	AH	0	7	8	8	8	9	0	08/13/97	EPO (Vanmaele)				
														

<u> </u>		OTHER DOCUMENTS (Including Author, Title, Date, Perlinent Pages, Etc.)		
	Al	Howard, Provisional Patent Application No. 60/015,134 filed March 29, 1996 for "Lac Derivatives"	tam	
		[5]		===
	L	.l	W.S.	3
			=	
		1500/Z	2907	7.3
			?	3

^{*}MINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SERIAL NO. ATTY. DO KET NO. FORM PTO-1449 09/897,755 38602/1220 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT \ APPLICANT: Peng Cho Tang et al. OIPE (C)(Use several sheets if necessary) FILING DATE: GROUP: 7/3/01 1627 PADEMAR

	BO	9	6	0	0	2	2	6	04.01.96	WOPCT (Buzzetti et al.)			ni	
	BE.	9	5	1	7	1	8		29.06.95	WOPCT (Buzzetti et al.)	<u>[]</u>	MAF		
	8F	9	1	1	3	0	5	5	05.09.92	WO/PCT (Buzzetti et al.)		0	m	
	BG	9	3	0	1	1	8	2	21.01.93	WOPCT (Buzzetti et al.)	<u>5</u>	2092	<	
	814	9	4	0	3	4	2	7	17.02.94	WO/PCT (Dobrusin et al.)	12/0/191	92	<u>C</u>	
	Bi	9	· 2	2	1	6	6	o	10.04.92	WOPCT (Dow)	9			
	BJ	9	1	1	5	4	9	5	17.10.91	WOPCT (Dow et al.)				
	ВК	0	5.	8	0	5	0	·2	01.94	₽O .		·		
	BL		8	7	8	5	3	9	06.53	Cermany			1	
	ВМ	2	6	8	9	3	9	7	08.10.93	France (Guillaume et al.)				
	BN		8	0	9	6	9	1	04.93.59	Creat Britian (Hull)				
	ВО	1	3	9	8	2	2	. 4	29.03.65	France (Imperial Chemical)				
	ВР	6	2	2	9	5	7	0	07.02.87	japan				
	BQ	6	2	3	9	5	6	4	02.87	Japan				
	BR	<u>.</u>	1	4	1	9	5	5	14.06.88	japan .				
	BS	9	4	,	0	2	0	2	11.05.94	WOPCT (christion et all)				
	вт		2	8	6	8	7	0	04.12.64	Australia (Murnane and Moore)				
-	BU	0	3	5	1	2	1	3	17.01.90	EPO (Nadler et al.)				
	BV	9	2	0	7	8	3	0	14.05.92	WOPCT (Nakanishi et al.)			,	
	BW	0	6	3	2	1	0	2	15.06.94	EPO (Roschiger)			:	
	BX	Ť	5	5	8	8	9	4	09.03.93	japan (Sakuda et al.)	-			
	BY	2	0	1	2	6	3	4	20.09.91	Canada (Salari)				
 	8Z	2	1	5	9	3	6	0	14.06.73	Cermany Scheer et al.)	<u> </u>			
	α	2	-	5	9	3	6	1	14.06.73	Cermany (Scheer et al.)				\vdash
	8	2	1	5	9	3	6	2	14.06.73	Cermany Scheer et al.)			I	\vdash
	8	2	1	5	9	3	6	3	14.06.73	Cermany (Scheer et al.)			T	
	8	 	8	3	5	4	7	3	18.05.60	Great Britain Senior)			1	Г
	Œ	8	8	0	7	0	3	5	22,09,88	WOPCT (Shiraishi et al.)	 	Ė	1	<u> </u>
	1	-	┯	0	3	7	3	6	06.05.92	WOPCT (Sports et al.)	 		1	\vdash
	⊕	9	2	 	 	┢	\vdash	┰		Cermany (Tomlinson)	\vdash		 	
	8	2	3	2	1	6	5	9	15.11.73 19.02.75	Great Britian (Tornlinson)	 	\vdash	\vdash	\vdash
	어	1	3	8	4	5	9	-		 	 	-	 	
	0	9	6	2	2	9	7	6	08/96	WOPCT	 	 	 	\vdash
	-	-	╀	-	┞	├	\vdash	-	-	 	+		 	\vdash
	-	├	┼-	-	├-		├-	├-	-		-			+-
	Ι.	I .	1	ŧ	í .	1	1	1	1	1	1	1	Í	1

1	a	9	6	2	2	9	7	6	08/96 W	XPCT
					Г	_				
EXAMINER	 Ŀ									DATE CONSIDERED:
		47-4-74			. i.e.	- cid	ered.	whet	her or not citatio	on is in conformance with MPEP 609; Drav

FORM PTO-1449	ATTY. DÜCKET NO. 38602-1220	SERIAL NO. 09/897,75 <u>5</u>	7
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT O P E Use several sheets if necessary)	APPLICANT: Peng Cho Tang e		FCI.
MAR 0 : 2012 5	FILING DATE: 7/3/01	CROUES - E	VED

 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Abramovitch et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," Chemistry and Industry 44:1871 (1967)
Abramovitch and Hey, "internuclear cyclisation," J. Chem. Soc. pp. 1697-1703 (1954)
Akbasak and Suner-Akbasak et-al., "Oncogenes: cause or consequence in the development of glial tumors," J. Neurol. Sci. 111:119-133 (1992)
Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990)
Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," Eur. J. Med. Chem. 28:653-657 (1993)
Andreani et al., "Synthesis of lacatams with potential cardiotonic activity," <u>Eur. 1, Med. Chem.</u> 28:825-829 (1993)
Andreani et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," <u>Eur. 1. Med. Chem.</u> 27:167-170 (1992)
Arteaga et al., "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice," <u>I. Clin. Invest</u> , 84:1418-1423 (1989)
Autrey and Tahk, "The Synthesis and Sterochemistry of Some Isatylideneacetic Acid Derivatives," <u>Tetrahedron</u> 23:901-917 (1967)
Bahner et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," <u>I. Med. Chem.</u> 12:721-722 (1969)
Bamfield et al., *Diels-Alder Reactions of Oxindolylideneacetone,* <u>I. Chem. Soc. (C)</u> pp. 1028-1030 (1966)
Baserga, "Oncogenes and the strategy of growth factors," Cell 79:927-930 (1994)
Baserga, "The insulin-like grwoth factor I receptor: a key to tumor growth?" <u>Cancer Res.</u> 55:249-252 (1995)
Blake and Jaques, "Anisotropic Effects in alpha-substituted methoxystilbenes," <u>I. Chem. Soc. Perkin</u> <u>11</u> pp. 1660-1663 (1973)
Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB</u> <u>1.</u> 6:3403-3409 (1992)
Bolen, "Nonreceptor tyrosine protein kinases," Oncogene 8:2025-2031 (1993)
Borsche et al., "Uber nielkernige kondersierte systeme mit heterocyclischen ringen," <u>Liebigs Ann.</u> <u>Chem.</u> 550:160-174 (1941)
Buzzetti et al., "Clinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48:615-636 (1993)
Canoira and Rodriguez, "Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex," <u>1. Heterocyclic Chem.</u> 22:1511-1518 (1985)
Chatten et al., "Substituted Oxindoles. Part VI. Polargraphic Reduction of Substituted trans-3-benzylideneindol-2(3H)-ones," 1. Chem. Soc. Perkin II pp. 469-473 (1973)
Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>I. Chem. Soc. Perkin II</u> pp. 615-619 (1984)
Coppola et al., "A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor," Mol. Cell. Biol. 14:4588-4595 (1994)

EXAMINER:	DATE CONSIDERED:
<u> </u>	<u>'</u>
Contraction and the second sec	i / id storm con D - ili il

INFORMATION DISCLOSURE STATEMENT APPLICANT: Peng Cho Tang et al. FILING DATE: GROUP:	FORM PTO-1449	ATTY. DÜLKET NO. 38602/1220	SERIAL NO. 09/897,755	
FILING DATE: GROUP: 2 - 5	30	1	AL OF THE AL	7
	/ ³⁶ ';	FILING DATE: 7/3/01' "	GROUP: 글 등 16청	

	· · · · · · · · · · · · · · · · · · ·
DF	Daisley, "Thin-layer chromatographic separation of some substituted 3-benzylidine-indol-2(3H)-ones," J. Chromatography 100:240-242 (1974)
DG	Dati et al., *Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells,* <u>Oncogene</u> 5:1001-1006 (1990)
DH	De Vries et al., "The Imp-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," Science 255:989-991 (1992)
DI	Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," 1. Immunol. Methods 15:61-69 (1988)
DJ	Dickson et al., "Tyrosine kinase receptor-nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992)
' DK	Elliott and Rivers, "Reduction of some oxindolylidene derivatives to 3-substituted oxindoles by sodium borohydride," <u>I. Org. Chem.</u> 29:2438-2440 (1964)
DI	Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," Cell 69:413-423 (1992)
DM	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human or Epidermal Growth Factor Receptor or HER2/neu Gene Product" Cancer Research 50:1550-1558 (1990)
DN	Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochem. Biophys. Res. Commun.</u> 161:851-858 (1989)
DO	Fingl and Woodbury, Chapter 1, pp.1-46 in <u>The Pharmacological Basis of Therapeutics</u> (5th edition),eds. Goodman et al., MacMillan Publishing Co., Inc., New York (1975)
DP	Floege et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," Kidney International 435:47-54 (1993)
DQ	Folkman and Shing, "Anglogenesis," <u>I. Biol. Chem.</u> 267:10931-10934 (1992)
DR	Folkman, "What is the Evidence that Tumors are Anglogenesis Dependent?" <u>Journal of the National Cancer Institute</u> 82:4-6 (1990)
DS	Goldring, "Cytokines and cell growth control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)
DT	Gottardis et al., "Estradioi-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen," <u>I. Steroid Biochem.</u> , 30(1-6):311-314 (1988)
DU	Hewgill and Stewart, "Phenanthrene-4,S-quinones: a Synthesis of Morphenol," <u>I. Chem. Soc. Perkin Trans. 1</u> pp. 1305-1311 (1988)
DV	Hodges et al., "Chemical and biological properties of some oxindolidyl-3-methines," <u>Canadian I.</u> <u>Chemistry</u> 46:2189-2194 (1968)
DW	Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein- Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 5:199-209 (1987)
DX	Houck et al, "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>i. Biol. Chem.</u> 267:26031-26037 (1992)
ΥC	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids," <u>Eur. I. Med. Chem.</u> 27:779-789 (1992)
DZ	tjaz et al., "The Conversion of o,β-Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," <u>I. Chem. Res. (S)</u> pp. 116 (1990)

EXAMINER:	•	DATE CONSIDERED:	

FORM PTO-1449	ATTY. DOCKET NO. 38602-1220	SERIAL NO. 09/897,755
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT O 1 P E (Use several sheets if necessary)	APPLICANT: Peng Cho Tang et al.	
MAR 0 1 2002 35	FILING DATE: 7/3/01	GROUP: 1627
PAUL MANUE		

EA	Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994)
EB	Katritzky et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," J. Heterocyclic Chem, 25:1287-1292 (1988)
EC	Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble-receptor," Proc. Natl. Acad. Sci. USA 90:10705-10709 (1993)
ED	Khalil and Abdel-Rahman, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," <u>J. Indian Chem. Soc.</u> 54:904-907 (1977)
EE	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature 362:841-844 (1993)
EF	Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," Exp. Cell Research 199:52-62 (1992)
EG	Klagsbrun and Soker, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993)
EH	Kobayashi et al., "Anti-tumor Activity of Indole Derivatives," Yakugaku Zasshi 97(9):1033-1039 (1977)
EI	Koch et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," Science 252:668-674 (1991)
EJ	Korc et al., "Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha," <u>I. Clin. Invest.</u> 90:1352-1360 (1992)
EK	Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity", " I. Immunol, Methods 64:313-320 (1983)
EL	Kovac and Stetlnova, "Furan derivatives LXXX. Synthesis and properties of substituted furfurylidenoxindoles," Chem. rvesu 30:484-492 (1976)
EM	Kumbae et al., "Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," Oncosene 7:627-633 (1992)
ĖN	Larock and Babu, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," <u>Tetrahedron Letters</u> 28:52991-5294 (1987)
EO	Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," <u>I. Cell. Biol.</u> 118:1057-1070 (1992)
EP	Macauley et al., "Autocrine function for insulin-like growth factor 1 in human small cell lung cancer cell lines and fresh tumor cells," Cancer Res. 50:2511-2517 (1990)
EQ	Mariani et al., "Inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994)
ER	Martin-Leàn et al., "On the Cyclization to the Elusive Amino-4H-pyran Ring," <u>Liebigs Ann. Chem.</u> pp. 101-104 (1990)
ES	Mirand et al., "A Synthetic Entry in the Aristotelia Alkalolds," I. Org. Chem. 47:4169-4170 (1982)
ET	Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," L. Immunol. Methods 65:55-63 (1983)
EU	Neber and Rocker, "Ueber die einwirkung voon benzaldehyden auf die freie o-aminophenylessigsaure," Chem. Ber. 56:1710-1717 (1923)
	EB EC ED EE EF EG EH EI EN EN EO EP EQ ER ES ET

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

	<u>-</u> :	=-1
FORM PTO-1449	ATTY. DUCKET NO. 38602-1220	SERIAL NO. ☐
LIST OF PATENTS AND OTHER ITEMS FOR APPRICANT'S INFORMATION DISCLOSURE STATEMENT O I PE One several sheets if necessary)	APPLICANT: Peng Cho Tang e	
MAR 0 1 2022	FILING DATE: 7/3/01	CROUPS - 2 . II
RADEMARK		

	£٧	Nodiff et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6- Substituted 9-Phenanthrenemethanols," <u>I. Med. Chem.</u> 14:921-925 (1971)
	EW	O'Sullivan and Rothery, "The Preparation and Possible Clinical Significance of 4'- Dialkylaminoisoindogenides," <u>Clinica Chimica Acta</u> 62:181-182 (1975)
	EX	Osborne et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)
	£Υ	Ozzello and Sordat, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)
	EZ	Pavlenko et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," <u>Dopov. Akad. Nauk Ukr. RSR</u> 7:64-66 (1980)
	FA	Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gilomas in vivo," Nature 359:845-848 (1992)
	FB	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7(6):334-339 (1994)
	FC	Ruveda and Gonzalez, "Geometric isomerism in benzylideneoxindoles," <u>Spectrochimica Acta</u> 26A:1275-1277 (1970)
,	FD	Rygaard and Povisen, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," Acta path. microbiol. scand, 77:758-760 (1969)
	FE	Sandberg-Nordqvist et al., "Characterization of Insulin-like growth factor 1 in human primary brain tumors," <u>Cancer Res.</u> 53:2475-2478 (1993)
	FF	Schindler et al., "Über Dibenz[b,f]-azocin-Derivate," Helvetica Chimica Acta 49:985-989 (1966)
	FG	Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," Neuron 9:383-391 (1992)
	FH	Schnierle et al., "Vilsmeier-Reaktion mit Pyrrol- und Pyrrolon-Derivaten," <u>Liebigs Ann. Chem.</u> 715:90-97 (1968)
	FI	Schuchter et al., "Successful Treatment of Murine Melanoma with Bryostatin 1," Cancer Research 51:682-687 (1991)
·	FJ	Selbert et al., "Clonal Variation of MCF-7 Breast Cancer Cells <i>In Vitro</i> and In Athymic Nude Mice," Cancer Research 43:2223-2239 (1983)
	FK	Shafie and Grantham, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," 1. Natl Cancer Institute 67(1):51-56 (1981)
	FL	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely realted to the fms family," Oncogene 5:519-524 (1990)
	FM	Shiraishi, "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987)
	FN	Shiraishi et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4- Hydroxycinnamamide Derivatives in Vitro," <u>Cancer Research</u> 49:2374-2378 (1989)
	FO	Shweiki, "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," Nature 359:843-845 (1992)
	FP	Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl.</u> <u>Cancer Inst.</u> 82:1107-1112 (1990)
	FQ	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," Science 244:707-712 (1989)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

FORM PTO-1449	ATTY. DOCKET NO.	SERIALINO.	Ê
	38602-1220	09/897;755	
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT OIPE (Use several sheets if necessary)	APPLICANT: Peng Cho Tang et	0 6 201 KTER 160	EIVE
MAR 0 , THE E	FILING DATE: 7/3/01	GROUPS: N	Ü
TRADEMARK.			

TAUESIA	
· FR	Songyang et al., "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk and Vav," Molecular and Cellular Biology 14:2777-2785 (1994)
F5	Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," Cell 72:767-778 (1993)
អ	Stetinova et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," Collection Czechoslov. Chem. Commun., 42:2201-2206 (1976)
fU	Sumpter and Miller, "Chapter IV - Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole Systems</u> , Interscience Publishers, Inc., New York, pp. 134-153 (1954)
FV	Tacconi et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," <u>1.C.S. Perkin II</u> pp. 150-154 (1976)
FW	Tacconi and Marinone, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," <u>Ricerca Scientifica</u> 38:1239-1244 (1968)
FX	Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," Mol. Blo. Cell 4:358A (1993)
FY	Thompson et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," <u>1. Chem. Soc. Perkin Trans. (1)</u> pp. 1835-1837 (1993)
FZ	Torp et al., "Expression of the epidermal growth factor receptor gene in human brain metastases," <u>AMPIS</u> 100:713-719 (1992)
GA	Triebs et al., "Uber isolndigolde Farbstroffe der Pyrrol-Reihe," <u>Liebigs Ann. Chem.</u> 702:112-130 (1967)
GB	Tuzi et al., "Expression of growth factor receptors in human brain tumours," <u>Br. I. Cancer</u> 63:227-233 (1991)
GC	Ullrich and Schlessinger, "Signal Transduction by Receptors with Tyrosine Kinase Activity," Cell 61:203-212 (1990)
. GD	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Grwoth Factor," <u>1. Biol. Chem.</u> 265:19461-19466 (1990)
GE	Varma and Gupta, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>I. Indian Chem. Soc.</u> 66:804-805 (1989)
GF	Voller et al., "Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980)
cc	van Dobeneck et al., "a, b'-Diindolylmethane und -methene. Der Urorosein-Chromophor," Zur Chemie des Indols VI:1347-1357 (1969)
СН	Wahl et al., "Chimle Organique - Sur les iso-indogenides," <u>C.R. Hebd. Seancest Acad. Sci.</u> 149:132-134 (july 1909)
GI	Walker, "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(B-Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>I. Med. Chem.</u> 8(5):626-637 (1965)
GJ	Walker, "Synthesis of a σ-(p-Aminophenyl)- and σ-(p-Chlorophenyl)-β-aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," <u>I. Med. Chem.</u> 8(5):583-588 (1965)
GK	Warri et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-1 Human Breast Cancer Cells In Vitro and in Nude Mice," Int. i. Cancer 49:616-623 (1991)
GL	Weidner et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma," New England J. Medicine 324:1-7 (1991)

EXAMINER:	DATE CONSIDERED:
FYAMINER: Initial if reference is considered, whether or not citation is	in conformance with MPEP 600: Draw line through

FORM PTO-1449	ATTY. DÜCKET NO. 38602-1220	SERIA 60.	
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT O 1.5 E Wilse several sheets if necessary)	APPLICANT: Peng Cho Tang et	al. 100	, , , , , , , , , , , , , , , , , , ,
MAR 0 , 2002 5	FILING DATE: 7/3/01	GROUP: 153	<u>כ</u>

	GM	Winkelmann et al., "Chemotherapeutically Active Nitro Compounds: 4. 5-Nitroimidazoles (Part 1)," <u>ArzneimForsch./Drug Res.</u> 27(II):2251-2263 (1977)
•	GN	Wright et al., "Cyclic Hydroxamic Acids Derived from Indole," JACS 78:221-224 (1956)
	GO	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," I. Cellular Physiology 152:448-457 (1992)
	GP	Young and Babbitt, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, a Reversible Redox Substrate at the Carbon Paste Electrode in Acidic Aqueous-Ethanolic Media," 1. Org. Chem. 47:1571-1572 (1982)
	GQ	Zhungietu et al., "Reaction of Indoles and 2-Ketoindolines With Some Aldehydes," <u>Institute of Chemistry</u> , <u>Academy of Science of theMoldavian SSR</u> , <u>Kishinev</u> pp. 34-37 translated from <u>Khimiya Geterotsiklicheskikh Soedinenii</u> 1:40-44 (1973)

EXAMINER:

DATE CONSIDERED:

<u> </u>	•••				7 ts			
FORM PTO-144	19			ATTY, DOCK	Ei NO.	SERIAL NO	ان.	
LIST OF P	ATEN	ITS AND OTHER ITEMS	FOR APPLICANT'S	38602-122	20	09/897,7	555	M R
	FORA	MATION DISCLOSURES	TATEMENT	APPLICANT: Peng Cho T			NI:	C
MAR : . m	*?\(\frac{1}{2}\)	Jse several sheets if neces	ssary)	FILING DATE 7/3/01		GROUP: 1627	1600,	G 2002
183	<u> </u>	<u> </u>					33	
182	¢Σ,		U.S. PATENT D	OCUMENTS				_
ENITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILI DA	NG TE
							-	
						1 1		

	r	γ	FOREIGN P	ATENT DOCUMENTS				
EXAMINER						SUB	TRANSL	ATION
INITIAL	ļ	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO
	AA	WO 99/10325	04.03.99	PCT (McNutt et al.)				
								<u> </u>

· · · · · · · · · · · · · · · · · · ·	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Arzneimittel-Forschung Drug Research 48(II):727-729 (1998)	-
A	Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997)	-
A	40(3):149-156 (1997)	
. A	1161 (1994)	j -
· A	and Related Compounds, Journal of Medicinal Chemistry 16(9):1043-1045 (1973)	
Α	Graziani et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanin Nucleotide Exchanger"," The Journal of Biological Chemistry 268(13):9165-9168 (19)	ne 93)
А	Kato et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-	
A	Maass et al., "Viral Resistance to the Thiazolo-Iso-Indolinones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," Antimicrobial Agents and Chemotherapy 37(12):2612-2617 (1993)	
A	Moreto et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," <u>Arzneimittel-Forschung Drug Research</u> 29(II):15 1564 (1979)	61-
A	European Journal of Pharmacology 36:221-226 (1976)	-
Α	Singh et al., "Indolinone Derivatives as Potential Antimicrobial Agents," Zentralbl. Mikrobiol. 144:105-109 (1989)	
Al	Singh et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxosprio (Azetidin-3', 4-Indol-2' Ones)," Bollettino Chimico Farmaceutico 133:76-79 (1994)	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not cita citation if not in conformance and not considered. Include a cop	tion is in conformance with MPEP 609; Draw line through

OKM PTO-1449	ATTY. DOCKET NO.	SERIAL NO.
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S	38602-1220	09/897,755
O 1 2 ENPORMATION DISCLOSURE STATEMENT	APPLICANT: Peng Cho Tang et al.	
(Use several sheets if necessary)	FILING DATE:	GROUP:
19	. 7/3/01	1627

PADEN	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AN	Soldi et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 ^{FAK}) in Human Endothelial Cells," <u>Oncogene</u> 13(3):515-525 (1996)
АО	Tsai et al., "The Effect of 3,3-Di-Pyridyl -Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," Neugrpharmacology 31(9):943-947 (1992)
АР	Zaman et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β-Receptor (β-PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57(1):57-84 (1999)
AQ	Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," Molecular Pharmacology 49:228-294 (1998)

MAR 0 6 2002
TECH CENTER 1600/2900

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation citation if not in conformance and not considered. Include a copy of	is in conformance with MPEP 609; Draw line through this form with next communication to applicant.

.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

-		
	ATTY, DOCK	SERIAL NO.
	38602 1220	09/897,75
1	APPLICANT.	

APPLICANT:
Peng Cho Tang et al.

FILING DATE: 7-3-01

GROUP:

1627

0 6 2002

_	A STATE AND IN
	▼.

			U.S. PATENT D	OCUMENTS			=======================================
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	ÑAME	cres	SU8 CLASS	FILING DATE 2290
	AA						29
	AB				•		2
	AC				. ·		
	AD	·	·				
	AE					·	
	AF						
	AG						
	AH .						
	AI						
·	ĀJ			•			
				-			

•	FOREIGN PATENT DOCUMENTS									
EXAMINÈR	1	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB	TRANS	TRANSLATION		
INITIAL		·		Cooning		CLASS	YES	NO		
·	AL	WO 96/32380	10/17/96	WO/PCT (Battistini)						
	AM	WO 96/22976	08/01/96	WO/PCT (Buzzetti)			•			
	AN.	WO 96/40116	12/19/96	WO/PCT (Tang)	·					
	AO		•							
	AP	,		,		•				

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	AQ	Andreani et al., "Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolylmethlene) 1,3-Dihydroindol-2-Ones," AntiCancer Research 16:3585-3588 (1996)
~	AR	Terrett et al., "Combinatorial Synthesis-The Design of Compound Libraries and their Application to Drug Discovery," Tetrahedron 51(30):8135-8173 (1995)
,	AS .	Coda et al., "3-(4-methylbenzilidene)-1-,3-dihydroindol-2-one," <u>Journal of the Chemical Society. Perkin Transactions 2</u> 4:615-620 (1984), DATABASE CROSSFIRE, Beilstein No. 6-21
	AT	Wahl, "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," Ann. Chim p. 350 (1926), DATABASE CROSSFIRE, Beilstein No. 2-21-00-00290
	AU ·	Elliot, "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," Journal of Organic Chemistry 29:2438-2440 (1964), DATABASE CROSSFIRE, Beilstein No. 5-24
	AV	·

EXAMINER:	DATE CONSIDERED:	
	<u></u>	



LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCI	٠.
38602-12	220

SERIAL NO.

<u>...09/897,755</u>

APPLICANT:

FILING DATE

Peng Cho Tang et al.

7-3-01.

GROUP:

			U.S. PATENT	DOCUMENTS			<u> </u>
EXAMENER INITIAL		OOCUMENT NUMBER	OATE	NAME	CLASS	SUB	1 4 (C) (C)
•	AA						320
	AB						3
	AC	,		•			
	AD						
	ΑE			·	•		
	AF			•			
	AG	•		•	·		
	AH						
	AI	• .					
	AJ			·			
	AK						

	FOREIGN PATENT DOCUMENTS								
EXAMINER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATIO		
INITIAL							YES	NO	
	AL	0 632 102	04/01/95	EPO (Roschger)			X		
	AM	WO 97/25986	07/24/97	WO/PCT (Sato)			х		
	AN	•							
	AO								
	AP								

AQ	·			
				
AR				
AS		·		
AT			·	
ΑÜ	·	•		
AV	•			•
AW	•			
AX ·				
AY				•
AZ				

DATE CONSIDERED:

<u>; </u>									
FORM	PTO-14	149.			ATTY. DOCKET NO.	9	ERIAL	207	755
rıż	T OF PA	TENTS AND OTHER ITEMS FOI ORMATION DISCLOSURE STAT	TEMENT	•	38602-1220 APPLICANT: Peng C. Tang et al.	L	09/	897.	<u> </u>
	612	Ese gyeral sheets if necessar)		FILING DATE: 7-3-01		ROUP:	162	 7
	HAR D	4 8000 W							
18	<u>. </u>		U.S. PATENT	DOCU	MENTS		-, -		
INITIAL	A TR	WE MAN DOCUMENT NUMBER	DATE	NAME		CLA	SS SUE		TUNG DATE
	1	·		_	· · · · · · · · · · · · · · · · · · ·			+	
<u> </u>				-	•			+-	
		·	<u> </u>			+	+-	+-	
			+	-				+	
				. —				+	
						_	1-	十一	
								1	
· · · · · · · · · · · · · · · · · · ·		• •							
		FO	REIGN PATEN	T DOC	UMENTS				-
EXAMÍNER INITIAL		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUB CLASS	TRANS	NO
·	· AA	1.398.224	29.03.65	Fran	ice				х
	AB	Unknown	12.10.92	Hun	gary .	<u> </u>			х
	<u> </u>					ļ			<u> </u>
	<u> </u>					 	<u> </u>		<u> </u>
	<u> </u>	<u> </u>		<u></u>			<u></u>		<u></u>
 ,	—т	OTHER DOCUMENTS (Including Auth	or, Title	e, Date, Pertinent Pages	, Etc.)			
	·			<u> </u>					
	AC	Beilstein Reg. No.: 252	929 Beilstein			·			
	-								, -
- .		- 							
		· · · · · · · · · · · · · · · · · · ·							
									
	·		•						
			•						· · · · · · · · · · · · · · · · · · ·
			_					,	
EXAMINER	li 			•.	DATE CONSIDERED	•			

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

MAR 0 6 2002
TECH CENTER 1600/2900

nformation Disclosure Statement - Section 9 PTO-1449

Page _1_ of _1_

FORM PT	O-1449	<u> </u>				ATTY. D	•	SERIAL N			
LIST.	OF PA	TENTS AND OTHER ITE	MS FOR APP	LICANT'S		38602-122 APPLICANT:	0	09/89	7,755		
	INFO	ORMATION DISCLOSU	RE STATEME	NT		Peng Cho T	ang et al			•	
	/ IF	Rissand shorts if				FILING DATE		GROUP:			
/	∕ 0′.	(Diseseveral sheets if n	iecessary)			. 7-3-0			162	7	
	MAR 0	1 2002 پي		•		· · · · · · · · · · · · · · · · · · ·		,		·	
18			U.S. P	ATENT D	OCU	MENTS			•		
EXAMINER	8 TRA	DOCUMENT NUMBER	DATE	NAME CL			· Cives	SUB		FILING	
		·				·	CLASS	CLASS		DATE	
				 		· · · · ·					
	 							 	+		
			· · · · · · · · · · · · · · · · · · ·				• .	1	 		
	- \					· .					
· .			FOREIGN	PATENT	DOC	CUMENTS					
EXAMI		·					T	 	TRA	NSLA-	
NER INITIAL		DOCUMENT NUMBER	DATE	C	OUN	NTRY	CLASS	SUB CLASS	YES	NO NO	
•							00.03	00/05	123	T	
										†	
			• •	•							
	<u> </u>	.									
					•					•	
	·	OTHER DOCUMEN	NTS (Includ	ing Autho	or, Tit	le, Date, Per	tinent Page	s, etc.)			
· · · · · · · · · · · · · · · · · · ·	**	Andreani et al., "Si imidazo [2,1-b] thi (1997)	ynthesis and azolylmeth	d potentia ylene)-2-	al coa indol	inthracyclinic inones," <u>Eur.</u>	activity of I. Med. Ch	substitute em. 32:91	d 3-(5- 9-924	•	
				•		•		ECH	=	RE	
					 	:		CENTER	MAR 0	Ю Ш	
								■ 3 160	6 200	<u> </u>	
EXAMINER	:		,		DATE	CONSIDERED	• .	1600/2900		Ö	
line throug	gh citat	itial if reference is conion if not in conformation applicant	nsidered, when the same and not	nether or i	not cit	ation is in cor clude a copy	formance w	vith MPEP	609; I)raw	

·	٠.						055141 110	Page 1	of 1
Form PTO-1449	9 .	U.S. DEPARTME			ATTY. DOCKET NO. 038602-12	20	SERIAL NO	^{).} '897,75!	5
MODIFIED)		PATENT AND IN	ADEMARK OFFIC	E	APPLICANT	03/03/7/03			
NEOE	PAATI	ON DISCLOSURE	CITATION			g-Cho TANG	, et al.		
OTP E	/ 1 PURE	ON DISCESSIVE			FILING DATE		GROUP AR	T UNIT	1627
0		veral sheets if nece	econ/l		07/03/20	01		ART_UN	
MAR 0 1 2002	(0.20 20							- 7	· · · · · ·
	\$/		U.S. PA1	EN	T DOCUMENTS	т —		1	
EXAMINE BANKS	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUB- CLASS	FILING I APPRO	F
		5,886,020	3/23/99	Ten	g et al.				
		5,792,783	8/11/99	Tan	g et al.				
		5,883,116	3/16/99	Tan	g et al.				
		5,883,113	3/16/99	Tan	g et al.				
		5,880,141	3/23/99	Tan	g et al.		1		
		5,409,903	4/25/95	Spa	da et al.	 	1		
		5,196,446			tzki Al		·		
		5,322,590	6/21/94	Sirc	ar et al.				
		5,522,655				-	 		
			EODEICH E	DAT	ENT DOCUMENTS				
					ENI DOCUMENTO		SUB-	TRANS	LATIC
F	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	CLASS	YES	NC
		-							
,		OTHER DOCU	MENTS (Includio	na A	uthor, Title, Date, Perl	tinent Pages.	Etc.)		
								-	
		Carey, F.A. and Su 55-60; Plenum Pre	ındberg, R.J., "Rea ss	ictio	n and Synthesis," <u>Advan</u>	ced Organic C	hemistry. Pa	<u>rt B</u> 3'" ed	lition:
		March, J.; Advance	ed Organic Chemis	try,	4 th edition; 109-111 and	127-130; John	Wiley & Sor	15	
		0	#A=#==================================		instantal Technologies As	Dave Discour	mr 2 Combi	notorial O	anni-
		Gordon, E.M. et al. Synthesis, Library	, Application of Co Screening Strategi	es, a	inatorial Technologies to and Future Directions,* <u>J</u>	i Drug Discove I. Medicinal Ch	emistry 37:10	18101181 OI 0, 138 5- 14	ganic 401
						 			
I									
	1				DATE CONSIDER	FD			
AVMINED					AND F AND SIDEK				
EXAMINER									
EXAMINER	INED.	Initial If citation	considered wh	ath	er or not citation is	in conforma	nce with N	PEP 609	9: Dra
EXAMi line th	rough				er or not citation is not considered. In		opy of this	form w	(f) ne
EXAMi line th	rough	citation if not ir					opy of this	form w	
EXAMi line th	rough	citation if not ir					opy of this	form w	(f) ne

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE			ATTY, DOCKET NO.		SERIAL NO.		
(MODIFIED)		PATENT AND TRADEMARK OFFICE		38602-1220		09/897,755			
188					APPLICANT			,	
OIP FINE	RMAT	ION DISCLOSURI	E CITATION .	•		Tang, et	al		
	% \				FILING DATE		GROUP AF	TINU T	
MAX U 1 2002	MAR 0 1 2007 Suppose several sheets if necessary)			7-3-01	1966	16	27 ·		
EXAMINER	<u>\$</u>	•	U.S. PA	ATEN	T DOCUMENTS				
EXAMINER		DOCUMENT					SUB-	FILING	DATE
INITIAL	REF	NUMBER	DATE		NAME	CLASS	CLASS	1 .	F PRIATE
	A1	5,565,324	Oct. 15, 1996	· Still,	et al.	435	6	 	, 1994
	A2	4,053,613	Oct 11, 1977 .	Rovi	nyak, et al.	424	246		7, 1975
	A3	. 4,002,749	Jan 11, 1977	Rovi	nyak	424	246	Aug 12	2, 1975
									•
							<u> </u>		
					•				· .
									····
	•		FOREIGN	PATI	ENT DOCUMENTS				*
	REF	DOCUMENT DATE		COUNTRY	CLASS	SUB-	TRANS	LATION	
`		NUMBER			<u> </u>	00.00	CLASS	YES	NO
	A4	WO 98 07695 A	Feb 26, 1998	Euro	pe	ļ		Х	
			,						
					······································				
			·			<u> </u>			<u> </u>
	•	OTHER DOCU	MENTS (includi	ng Au	ithor, Title, Date, Pert	inent Pages,	Etc.)		
									•
						•	哥	·	
				•			- 2		
	SE MAR O))
			•		•		Š	U	
			-, -, -, -, -, -, -, -, -, -, -, -, -, -				<u></u>		
EXAMINER					DATE CONSIDER	ED			
+ EXAI	MINER:	Initial if citation	considered, wi	hethe	er or not citation is i	n conforma	nce with M	PEP 609	; Draw
com	nunicat	ion to applicant.	contormance	and	not considered. Inc	any co	py or this	iorm Wil	xsn ii
									

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information untess it contains a valid OMB control

,

nu <u>mper.</u>							
	Substitute	for form 1449E	I/PTO		OIPE		
	INFORMAT	TION DISCLO	SURE	Application Number	09/897,755	7	7
	STATEME	NT BY APPL	ICANT	Filing Date	07/03/2001		اف
				First Named Inventor	Peng Cho TANG	, MAR 2 6 2004	
				Group Art Unit	1626	i MW. C. o. mon.	द्व
	(use as many	sheets as ne	cessary)	Examiner Name	Sonya N. Wright	3	8
Sheet	1	of	1	Attorney Docket Number	034536-0107	7	<u> </u>
						QAUE	

					DREIGN PATENT DOCUMEN		Dance Column Lines	
Examiner Cite No.1	Cite Foreign Patent Document				. Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	I
	No.1	Office	Number ⁴	Kind Code ³ (il known)	Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	۲
	A1	EΡ	0 252 713	81	PFIZER INC.	09-12-1990		
								Γ
				-	<u></u>			<u> </u>

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	7				
	A2	DESIMONI et al., "Catalysis with Inorganic Cations. V.1 Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium Perchlorate on Chemoselectivity," <u>Tetrahedron</u> , 1996, pp. 1200-12018. Vol. 52, No. 38, Elsevier Science Ltd.					
	А3	GIBSON et al., "Cleavage of Halogenobenzophenones by Potassamide in Ammonia; New Routes to Xanthem- and Thioxanthen-9-ones," <u>J.C.S. Perkin I</u> , 1975, pp. 155-160					
	A4	KULKA et al., "I-Butyl as a Blocking Group in the Synthesis of o-Hydroxybenzophenones," November 5, 1954, pp. 5469-5471					

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

^{*}EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-latter code (WiPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as Indicated on the document under WiPO Standard ST. 16 if possible. ⁶Applicant is to place e check mark here if English language Translation is attached.